Affiliation:
1. Department of Pharmaceutics, School of Pharmacy , University of Washington , Seattle , Washington , USA
Abstract
Abstract
Pregnant women are often complicated with diseases that require treatment with medication. Most drugs administered to pregnant women are off-label without the necessary dose, efficacy, and safety information. Knowledge concerning drug transfer across the placental barrier is essential for understanding fetal drug exposure and hence drug safety and efficacy to the fetus. Transporters expressed in the placenta, including adenosine triphosphate (ATP)-binding cassette efflux transporters and solute carrier uptake transporters, play important roles in determining drug transfer across the placental barrier, leading to fetal exposure to the drugs. In this review, we provide an update on placental drug transport, including in vitro cell/tissue, ex vivo human placenta perfusion, and in vivo animal studies that can be used to determine the expression and function of drug transporters in the placenta as well as placental drug transfer and fetal drug exposure. We also describe how the knowledge of placental drug transfer through passive diffusion or active transport can be combined with physiologically based pharmacokinetic modeling and simulation to predict systemic fetal drug exposure. Finally, we highlight knowledge gaps in studying placental drug transport and predicting fetal drug exposure and discuss future research directions to fill these gaps.
Funder
National Institute on Drug Abuse
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Reference84 articles.
1. Andrade, SE, Gurwitz, JH, Davis, RL, Chan, KA, Finkelstein, JA, Fortman, K, et al.. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004;191:398–407. https://doi.org/10.1016/j.ajog.2004.04.025.
2. Glover, DD, Amonkar, M, Rybeck, BF, Tracy, TS. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am J Obstet Gynecol 2003;188:1039–45. https://doi.org/10.1067/mob.2003.223.
3. Mitchell, AA, Gilboa, SM, Werler, MM, Kelley, KE, Louik, C, Hernandez-Diaz, S. National Birth Defects Prevention S: medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1–8. https://doi.org/10.1016/j.ajog.2011.02.029.
4. Mofenson, LM. Centers for disease C, prevention USPHSTF: U. S. public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Recomm Rep (Morb Mortal Wkly Rep) 2002;51:1–38. quiz CE31–4.
5. Gozar, L, Gabor-Miklosi, D, Toganel, R, Fagarasan, A, Gozar, H, Toma, D, et al.. Fetal tachyarrhythmia management from digoxin to amiodarone-A review. J Clin Med 2022;11:804. https://doi.org/10.3390/jcm11030804.